1. Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication

   • Nur Hezrin Shahrin
   • Carol Wadham
   • Susan Branford

   Chronic Myeloid Leukemias (V Oehler, Section Editor) Open access 06 August 2022 Pages: 171 - 180

   

2. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

   • John Joson Ng
   • S. Tiong Ong

   Chronic Myeloid Leukemias (V Oehler, Section Editor) 19 October 2022 Pages: 181 - 197

   

3. CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions

   • Emilia Scalzulli
   • Ida Carmosino
   • Massimo Breccia

   Chronic Myeloid Leukemias (V Oehler, Section Editor) 20 October 2022 Pages: 198 - 205

4. Value in Myeloma Care: Myth or Reality

   • Evguenia Ouchveridze
   • Katherine Berger
   • Ghulam Rehman Mohyuddin

   Health Economics (N Khera, Section Editor) 30 August 2022 Pages: 206 - 216

   

5. Precision Medicine in Myeloid Malignancies: Hype or Hope?

   • Shristi Upadhyay Banskota
   • Nabin Khanal
   • Vijaya Raj Bhatt

   Health Economics (N Khera, Section Editor) 16 August 2022 Pages: 217 - 227

   

6. Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation

   • Neel S. Bhatt

   Health Economics (N Khera, Section Editor) 04 October 2022 Pages: 228 - 242

7. Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults

   • Ginna Granroth
   • Nandita Khera
   • Cecilia Arana Yi

   Health Economics (R Mesa) Open access 19 September 2022 Pages: 243 - 253

   

8. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms

   • Anmol Baranwal
   • Christopher N. Hahn
   • Devendra K. Hiwase

   Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 20 August 2022 Pages: 254 - 265

   

9. Pediatric Germline Predisposition to Myeloid Neoplasms

   • Christineil Thompson
   • Sydney Ariagno
   • Mira A. Kohorst

   Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 19 September 2022 Pages: 266 - 274

   

10. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies

    • Himachandana Atluri
    • Yoheved S. Gerstein
    • Courtney D. DiNardo

    Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 24 October 2022 Pages: 275 - 285

    

11. Bispecific Antibodies for the Treatment of Multiple Myeloma

    • Scott R. Goldsmith
    • Shawn Streeter
    • Fahrettin Covut

    T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 27 August 2022 Pages: 286 - 297

    

12. Circulating Tumor DNA in Lymphoma

    • Swetha Kambhampati
    • Jasmine Zain

    T-Cell and Other Lymphoproliferative Malignancies (R Mesa, Section Editor) 10 October 2022 Pages: 298 - 305

13. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma

    • Arleigh McCurdy
    • Alissa Visram

    Multiple Myeloma (Prashant Kapoor, Section Editor) 22 November 2022 Pages: 306 - 318

14. Molecular Pathogenesis of Myeloproliferative Neoplasms

    • Benjamin Rolles
    • Ann Mullally

    Myeloproliferative Neoplasms (P Bose, Section Editor) 07 November 2022 Pages: 319 - 329